Biotechnology

Vistagen Therap

VistaGen Therapeutics Nasal Fasedienol Phase 3 Trial for Social Anxiety Fails to Meet Primary Endpoint

Vistagen Therap released FY2026 Semi-Annual earnings on November 13 After-Market EST, actual revenue USD 502K, actual EPS USD -1.0195

Vistagen Therap released FY2026 Q2 earnings on November 13 After-Market (EST), actual revenue USD 258K (forecast USD 145.8K), actual EPS USD -0.5431 (forecast USD -0.476)

Vistagen Therap to release FY2026 Q2 earnings on November 13 After-Market EST, forecast revenue USD 145.8 K, EPS USD -0.476

Analyst Minter Gives VistaGen a Strong Buy Rating

Vistagen Therap released FY2026 Q1 earnings on August 7 After-Market (EST), actual revenue USD 244K (forecast USD 215.67K), actual EPS USD -0.4727 (forecast USD -0.4733)

Vistagen Therap to release FY2026 Q1 earnings on August 7, 2025, After-Market EST, with forecasted revenue of USD 215.67 K and EPS of USD -0.4733

VistaGen Therapeutics Reports Better-than-Expected Q4 Earnings and Updates fasedienol Drug Progress

William Blair Reiterates VistaGen Outperform Rating

Vistagen Therapeutics Reports Exceeding Earnings Per Share Expectations and Stock Price Increase

Vistagen Therap released FY2025 earnings on June 17 During-Market (EST), actual revenue USD 486 K (forecast USD 710 K), actual EPS USD -1.6652 (forecast USD -1.7366)

Vistagen Therap released FY2025 Q4 earnings on June 17 During-Market (EST), actual revenue USD -15 K (forecast USD 209.33 K), actual EPS USD -0.432 (forecast USD -0.4966)

VistaGen Therapeutics to Report Q2 2025 Earnings

Vistagen Therapeutics Inc Sees EPS Loss of 50 Cents, 59.9% Revenue Growth

VistaGen Therapeutics Inc. to Release 2025 Fiscal Year Financial Results

Vistagen Therap to Release FY2025 Earnings on June 17 During-Market EST, Forecast Revenue USD 710K, EPS USD -1.7366

VistaGen Therapeutics CEO to Attend Jefferies 2025 Global Life Sciences Conference

VistaGen to Present New Insights at American College of Neuropsychopharmacology Annual Meeting

Vistagen Therap released FY2025 Q3 earnings on February 13 After-Market (EST), actual revenue 234K USD (forecast 179.25K USD), actual EPS -0.4587 USD (forecast -0.51 USD)

Vistagen Therap released FY2025 9 Months Earnings on February 13 After-Market (EST), with actual revenue of 501 K USD and EPS of -1.2325 USD

A SPAC III Acquisition

PicoCELA

Davis Commodities

Society Pass

ECD Automotive Design

Gauzy

Bristol-Myers Squibb Company

A SPAC III ACQUISITION CORP. COM NPV CL A (SUBS/RTS)02/01/2026

Paranovus ENT Tech

Cue BioPharma

ADMA生物制药

Kiniksa Pharmaceuticals

Stoke Therapeutics

Rigel制药

OpGen

福泰制药

再生元制药

阿里拉姆制药

Argenx

百济神州

Style Score

Growth Score

Revenue YoY

Net Profit YoY

Value Score

P/B Ratio

Dividend Ratio

Size Score

Market Cap Score

Market Cap

Revenue Score

Revenue

Multi Score

Profit Score

Profit Margin

Gross Margin

Total Assets YoY

Net Assets YoY

Cash Score

Cash Flow Margin

OCF YoY

Operating Score

Turnover

Debt Score

Gearing Ratio

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap